

November 17, 2022

The Honorable Rosa DeLauro  
Chair  
Committee on Appropriations  
U.S. House of Representatives  
Washington, DC 20515

The Honorable Patrick Leahy  
Chair  
Committee on Appropriations  
U.S. Senate  
Washington, DC 20510

The Honorable Kay Granger  
Ranking Member  
Committee on Appropriations  
U.S. House of Representatives  
Washington, DC 20515

The Honorable Richard Shelby  
Vice Chair  
Committee on Appropriations  
U.S. Senate  
Washington, DC 20510

Dear Chairwoman DeLauro, Chairman Leahy, Ranking Member Granger, and Vice Chairman Shelby:

The Endocrine Society urges Congress to complete the appropriations process for fiscal year (FY) 2023, including robust funding for the National Institutes of Health (NIH). Continued investment in the NIH is critical to further our understanding of endocrine disorders such as diabetes, obesity, cancer, and infertility, among many other diseases affecting millions of Americans.

We respectfully request that Congress pass at least the House Appropriations Committee adopted level of \$47.4 billion, which will support the continued bipartisan support and growth of NIH-funded research. Continued investment in scientific discoveries accelerates the development of breakthrough cures, creates jobs, and enhances the U.S.'s global leadership.

The Endocrine Society also recommends any funding for the Advanced Research Projects Agency for Health (ARPA-H) be provided in addition to that \$47.4 billion, to ensure that funding for the new entity supplements, not supplants, funding for the 27 Institutes and Centers and the Office of the Director of the NIH. While complementary, the NIH and ARPA-H have distinct and critical missions and should therefore be budgeted separately.

We urge Congress to swiftly finalize a spending package for FY 2023. While a continuing resolution (CR) averts a government shutdown, funding the NIH at FY 2022 levels does not account for substantial increases in biomedical research inflation or new opportunities to invest in finding cures. Steady and predictable funding increases are essential for the biomedical research workforce to maintain momentum and meet emerging public health challenges.



The Endocrine Society thanks Congress for the past 7 years of bipartisan support for sustained increases in NIH funding. We strongly support at least \$47.4 billion for the NIH, with separate funds for ARPA-H, in FY 2023.

Sincerely,

A handwritten signature in black ink that reads "Ursula Kaiser".

Ursula Kaiser, MD  
President  
Endocrine Society